register

News & Trends - Biotechnology

Merck and Microsoft partnerships support Australian-developed COVID-19 vaccine

Health Industry Hub | August 31, 2020 |

Biotech News: COVAX-19 is the first Australian-developed COVID-19 vaccine to pass phase I clinical trials in Australia successfully. Phase II clinical trials are set to begin in September 2020.

Professor Nikolai Petrovsky is the Director of Endocrinology at Flinders Medical Centre, a Professor in the School of Medicine at Flinders University and the founder of Vaxine Pty Ltd, an Adelaide-based biotechnology company specialising in pandemic vaccine design.

COVAX-19 vaccine comprises a recombinant spike protein antigen formulated with Vaxine’s proprietary Advax adjuvant, which drives a potent T cell and neutralising antibody response against the target virus.

The Microsoft AI and Azure cloud capabilities will help the company accelerate clinical testing of its COVAX-19 vaccine.

“Large international Phase III vaccine trials are extraordinarily complex and generate vast amounts of data that needs to be efficiently processed”, says Vaxine Research Director, Flinders University Professor Nikolai Petrovsky.

“Supported by Microsoft technology, we aim to collect and analyse the COVAX-19 trial data in real time, rather than waiting until the end of the trial before seeing if the vaccine is working, which is the traditional process.”

Merck Life Sciences, Managing Director, Rebecca Lee, conducted a recent Q&A video interview with Professor Nikolai Petrovsky.

Join 22,000+
industry professionals
in accessing the latest 
industry news, scientific insights & engaging professional development 
content from
Health Industry HubTM, 
the ONLY one-stop-hub
connecting Australia’s 
Pharma, MedTech & Biotech
industry professionals. Register now.

Merck has a long-standing relationship with Sypharma and Vaxine for more than 10 years, supporting the manufacture of Advax adjuvants with manufacturing solutions, single-use, filtration products and process development expertise.


News & Trends - MedTech & Diagnostics

Government commissions review as 70% of private hospitals face financial crisis

Government commissions review as 70% of private hospitals face financial crisis

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: Despite playing a crucial role in providing acute care and surgical services, a staggering 70% of […]

More


News & Trends - Pharmaceuticals

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Pharmacy Guild echoes ACCC red flags over Chemist Warehouse-Sigma deal

Health Industry Hub | June 14, 2024 |

Pharma News: The Pharmacy Guild of Australia has echoed the significant concerns of the Australian Competition and Consumer Commission (ACCC) […]

More


News & Trends - MedTech & Diagnostics

Competition watchdog raises concerns over cancer care provider's expansion plans

Competition watchdog raises concerns over cancer care provider’s expansion plans

Health Industry Hub | June 14, 2024 |

MedTech & Diagnostics News: A leading provider of cancer care services in Australia, faces scrutiny from the Australian Competition and […]

More


News & Trends - Biotechnology

Aussie biotech secures first local CAR T patent

Aussie biotech secures first local CAR T patent

Health Industry Hub | June 13, 2024 |

Biotech News: A Melbourne-based biotechnology company which specialises in developing immune cell therapies for cancer treatment, has been granted its […]

More


This content is copyright protected. Please subscribe to gain access.